Bio-Rad Laboratories, Inc.

Análisis de la acción Bio-Rad Laboratories, Inc. (BIO)

$364.820

+2.408 (+0.66%)Al cierre

Loading chart…
Máximo
368.540
Apertura
364.900
Precio medio ponderado por volumen
364.41
Volumen
247.83K
Capitalización
7.76B
Mínimo
359.880
Importe
90.31M
EV/EBITDA, TTM
22.48

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

www.bio-rad.com

Análisis de IA of Bio-Rad Laboratories, Inc. (BIO)

Mantener

Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.

Recomendaciones de analistas (4)

-6.80% Potencial de caída
Comprar
4 Comprar
0 Mantener
0 Vender
Actual: 364.82
Mínimo
340.00
Promedio
340.00
Máximo
340.00

RBC Capital

2026-08-07

Precio objetivo

$390

Superar al mercado

Wells Fargo

2026-05-25

Precio objetivo

$310

Equal Weight

RBC Capital

2026-05-14

Precio objetivo

$320

Superar al mercado

Wells Fargo

2026-05-01

Precio objetivo

$290

Equal Weight

Citi

2026-04-07

Precio objetivo

$300

Neutral

Métricas de valoración

El PER previsto actual de Bio-Rad Laboratories, Inc. (BIO) es 41.32, frente a su media de 5 años de 33.15.

PER previsto

Valor razonable
Media 5A P/E
33.15
P/E actual
41.32
Sobrevalorada
41.39
Infravalorada
24.91

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
20.62
EV/EBITDA actual
22.48
Sobrevalorada
26.72
Infravalorada
14.52

Precio/ventas previsto

Valor razonable
Media 5A P/S
4.01
P/S actual
3.70
Sobrevalorada
5.33
Infravalorada
2.69

Escenarios de precio de Alphio AI para BIO

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BIO

$211.45

Precio del escenario

B

Base

Base · 50%BIO

$204.69

Precio del escenario

B

Bajista

Bajista · 25%BIO

$154.89

Precio del escenario

Ballenas con BIO en cartera

F

First Pacific Advisors, LP

+ Con en carteraBIO

+2.03%

Rentabilidad a 3 meses

H

Hosking Partners LLP

+ Con en carteraBIO

+1.54%

Rentabilidad a 3 meses

A

Ariel Investments, LLC

+ Con en carteraBIO

-3.36%

Rentabilidad a 3 meses

D

Deerfield Management Company, L.P.

+ Con en carteraBIO

-6.90%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-24 (ET)

06:30:00

Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions

2026-08-04 (ET)

17:00:00

Bio-Rad Implements Restructuring Plan Estimated Costs Up to $90 Million

16:30:00

Bio-Rad Reports Q2 Revenue of $651M, Beating Expectations

16:30:00

Company Expects 2026 Non-GAAP Revenue to Decline Approximately 3%

2026-07-21 (ET)

10:30:00

Sartorius Shares Drop After Competitor Earnings Report

Noticias

Preguntas frecuentes sobre BIO, respondidas por Alphio AI

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.

4 analysts cover BIO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 340.00.

Comunidad

Más ↗
TrendCircuit13/9/2026

Didn't do anything, just went to the bathroom, and when I came back the chart had already done the work for me. When the market dumped early on, $BIO's bounce looked weak no matter how you read it. Every step down from the high came with volume, but the rebound kept getting lighter. Overhead trapped positions were pressing down clearly, funds just wanted to use the bounce to exit, nobody really wanted to buy. I was watching the short direction at 0.03161, with protection set at the upper edge of the bounce platform. At the time I only reminded one thing: don't try to catch a bounce in the early stage of a breakdown. If your hands are itching, go to the bathroom and wash your face. Came back and refreshed, price had already reached 0.02549, position return sitting at +1376.01%. Everyone on board should be feeling good. I took 80% off the table first, moved protection on the remaining 20% to breakeven. If it keeps dropping, let it drop, if it breaks the previous low there's another leg to capture; if it bounces back, this trade won't turn from profit into loss. Risk control done upfront is called being rational; cutting after losses is called cutting your losses. Don't chase shorts now, wait for a bounce to a structural level before acting. If the next shot doesn't come, wait patiently. The market won't only open its door once. $ADA $ETH

Mostrar más
TrendCircuit11/9/2026

I was about to go vent on the forum, then I checked my balance and decided to let it go. The market is always right 😮💨 When the morning session dumped, $BIO bounced and it actually looked decent for a moment. But the more I watched the order book, the more something felt off. Every push up came with no volume, a classic sign of weak follow-through. That kind of bounce looks lively, but nobody is actually stepping in to buy. The chart keeps teaching you lessons, most people just choose to sleep through class. I went ahead and opened a short at 0.03161. Someone said I was late to the trade. I didn't bother arguing, just waited for the result. Price just dropped to 0.02504, and my position PnL hit +1479.26%. It was slow at first, but once it moved, it really moved. Feels good. Nailing the rhythm matters more than anything 😎 I took 80% off the table and moved my stop on the remaining 20% back to breakeven. Whether it bounces from here or keeps grinding down, I won't be stressed either way. The prerequisite for compounding is staying alive. The shortcut to getting rich is usually going to zero. I'd rather miss a limit-up than try to catch a falling knife and end up with bloody hands. Don't chase here. Chasing at key levels is how you get hurt. I'll wait for the next signal. $XRP $LAB

Mostrar más
TrendCircuit11/9/2026

I opened the charts this morning, rubbed my eyes, and gave myself a little slap to make sure I wasn't seeing things. No trades, no analysis, just pure luck and stubbornness. Saying that record out loud feels embarrassing, but honestly, it feels great. Panic comes from having no plan, losses come from overthinking. I just sat there quietly watching it perform. When the screen was full of green, some people were panicking, but I found it interesting. Thinking back to a few days ago, the last look before bed, the trend clearly had no strength, the bounce was weak, and volume wasn't following at all. Funds wanted to push it up, but even they didn't dare enter. The fake breakout smell was right in your face. My only thought at the time was that this kind of bounce wouldn't last past the third watch. Short above 0.03161, now $BIO is at 0.02458, unrealized gain +1573.54%. This one was just the market in a good mood, handing money over. But even with the win, position management still matters. Everyone note the position moves: take profit on 80% first to lock in gains, move the stop on the remaining 20% to near cost, and let it run a bit. Risk control done upfront is called being rational; cutting after a loss is called a last resort. Don't get jealous of this level now, this isn't the time to chase. If you missed the rhythm, you missed it. Wait for a more comfortable spot next round. I'll keep watching the charts and call it as soon as there's a signal. The market never lacks opportunities, it lacks the patience to wait. Everyone keep your hands tied. $SNDK $SOL

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar